Search

This Handbook on cancer biology comprehensively reviews the current status of the oncobiology of major cancer types, cancer detection and treatment strategies, principles and processes of cancer drug development, and nanomedicine and other emerging cancer medicine applications to cancer diagnosis and treatment. The book also provides practical and implementable nutritional guidance in cancer prevention, treatment, and quality of life for cancer survivors. It discusses pharmacogenetics strategies for predicting cancer prognosis and treatment exposure, response, and toxicity. Further, it presents bioinformatics approaches for predicting anti-cancer drugs and drug combinations based on the multi-omic data, including transcriptomics, toxicogenomics, functional genomics, and biological networks. The Handbook also examines major factors and pathways that regulate cancer stem cells development and discusses potential targeted therapy for cancer stem cells. The book explores the application of the CRISPR/Cas9-based gene-editing technique in basic cancer research, diagnosis, and treatment of cancer. This Handbook is an invaluable source for oncologists, researchers, public health specialists, epidemiologists, and policy makers.​

This reference book compiles together different animal models in cancer research. It provides knowledge and a better understanding of the advancement of the molecular and cellular mechanisms associated with the progression, formation, and clinical results of various types of cancer from the evidence collected from animal models utilized for cancer research. It discusses animal models for screening anti-cancer drugs and exploration of gene therapy. It presents different methods used to construct cancer animal models and the progress of each animal model in tumor research. The book also highlights the applications of genetic engineering, including CRISP/Cas9, in designing and developing animal models for cancer research. Further, it discusses strategies for modeling animals for investigating growth, metastasis, tumor-associated inflammation and microenvironment, cancer stem cells, tumor heterogeneity, and therapeutic resistance. This book is s a valuable resource for basic and translational cancer researchers, clinicians, and health care.

This book provides detailed information on the etiology, pathogenesis, diagnosis, prognosis, and treatment strategies for breast cancer. The first section of the book presents epidemiology, risk factors, histopathological, immunohistochemistry, and molecular subtypes of breast cancer based on the receptor status. It also discusses the association of breast cancer with other hormone-sensitive cancers. The second section of the book covers cover BRCA1 and BRCA2-associated breast carcinogenesis, early-stage progression of breast cancer, and noninvasive biomarkers for the early detection of breast cancer. It also discusses the role of epigenetic modifications and non-coding RNAs in breast cancer metastasis and explores these as the biomarkers and therapeutic targets for breast cancer therapy.Further, it discusses the role of fibrinolytic mechanisms and circulating tumor cells in breast cancer diagnosis, prognosis, and treatment. The book also provides an update on oral poly(ADP-ribose) polymerase (PARP) inhibitors to treat breast cancer. Finally, it offers potential new options for personalized therapies for breast cancer patients, including optimizing drug dosage and identifying genetic changes associated with cancer symptom occurrence and severity.

Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest advances in anti-cancer drug design and discovery. In each volume, eminent scientists contribute reviews relevant to all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The book series should prove to be of interest to all pharmaceutical scientists involved in research in anti-cancer drug design and discovery. The book series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field. The eleventh volume of the series focuses on reviews on targeted therapies and drug delivery systems. This volume covers the following topics: - PI3K/Akt/mTOR Pathway in Acute Lymphoblastic Leukemia Targeted Therapies - Polymeric Nanomedicines in Treatment of Breast Cancer: Review of Contemporary Research - Treatment of Lung Cancer in the New Era - Oral Administration of Cancer Chemotherapeutics Exploiting Self-Nanoemulsifying Drug Delivery System: Recent Progress and Application - Targeting Approaches for the Diagnosis and Treatment of Cancer

This book concisely describes the role of omics in precision medicine for cancer therapies. It outlines our current understanding of cancer genomics, shares insights into the process of oncogenesis, and discusses emerging technologies and clinical applications of cancer genomics in prognosis and precision-medicine treatment strategies. It then elaborates on recent advances concerning transcriptomics and translational genomics in cancer diagnosis, clinical applications, and personalized medicine in oncology. Importantly, it also explains the importance of high-performance analytics, predictive modeling, and system biology in cancer research. Lastly, the book discusses current and potential future applications of pharmacogenomics in clinical cancer therapy and cancer drug development.

This book is a state-of-the-art overview of cancer regional therapy (CRT) for the surgeons and interventional radiologists active in CRT development and research. The goals of this book are 1) to review the theory and practice of cancer regional therapies including pharmacology, devices, techniques, and workflow, 2) illustrate the most common procedures performed in the interventional and operating rooms, and 3) discuss data supporting use of CRT. This is meant to be a definitive text on the theory and practice of CRT. It begins with a summary of the history, technical principles that underlie regional therapy. The following parts discuss current data and practice in peritoneal, liver, limb, pleural and other sites. Included in the practice are considerations of workflow and financial issues revolving around CRT. Novel techniques and therapies under investigation are presented to inform the direction of the field. Cancer Regional Therapy summarizes the history, current technology, common procedures, and future prospects in this field and includes procedures from many surgical and interventional radiologic disciplines.

Unravelling the intricate cell signalling networks and their significance in cancer poses major intellectual challenge. Keeping this in mind, the book aims at understanding the mechanism of action of different proteins and their complexes in the cancer signalling pathways. Hence, the proposed book that comprises 20 chapters provides a comprehensive introduction on cell signalling, its alterations in cancer, molecules that have been popular targets as well as the ones that are emerging as targets. In addition, it discusses different forms of therapy that are coming up for its treatment. Other than that, a major portion of the book is focused on studying different disciplines at the interface of biology and other areas of science that are being used to understand cancer biology in depth.

This book presents the latest scientific knowledge on inherited and acquired bone marrow failure syndromes, describing the advances in understanding of genetics and pathophysiology that have been achieved as a result of high-throughput DNA sequencing, RNA expression studies, and modern biochemistry techniques. The full range of relevant conditions is covered, including acquired aplastic anemia, Fanconi anemia, ribosomopathies, telomeropathies, dyskeratosis congenita, Shwachman-Diamond syndrome, Diamond-Blackfan anemia, and congenital neutropenias and thrombocytopenias. In addition, it is explained how the study of these rare diseases has uncovered important new science and elucidated the pathophysiology of more common hematological and oncological diseases. A treatment-specific chapter describes options ranging from the conventional to the cutting edge. Bone Marrow Failure will be of value for both trainee and practicing hematologists and oncologists.

In this book, the authors present current research in the study of non-small cell lung cancer. Topics discussed include the preclinical and clinical advances of epigenetics in lung cancer; therapeutic antibodies and non-coding RNAs (ncRNAs) in non-small cell lung cancer; molecular profiling in lung cancer specimens leads to targeted therapeutic options in patients with non-small cell lung carcinoma; the role of radiation dose escalation in the treatment of stage III locally advanced inoperable non-small cell lung cancer; and mechanisms of resistance to EGFR inhibitors.

This book highlights the importance of phytochemicals and mitochondria in cancer prevention and therapy. Recent scientific discoveries have identified that naturally occurring biologically active compounds (i.e. phytochemicals) target multiple steps of tumorigenesis leading to the inhibition or delay in cancer progression. Mitochondria, organelles within a cell, are a critical target for phytochemicals in regulating the initiation, promotion, and progression of cancer. The book is divided into three parts to better communicate the important findings related to phytochemicals and mitochondria in cancer research. The first part describes updates on environmental and genetic factors causing cancer initiation and progression, the role of mitochondria function in regulating the process of tumorigenesis, and the role of mitochondria in regulating cell death such as apoptosis, autophagy, and necroptosis. The second part focuses on the elucidation of key target proteins that could be exploited for cancer prevention, an the role of phytochemicals in cancer prevention, updates on basic research related to phytochemicals action critical for cancer prevention, and updates on translational knowledge on cancer prevention by phytochemicals. The third part provides updates on phytochemicals targeting mitochondria for cancer therapy, an overview of action of phytochemicals on cancer stem cells, updates on the role of microRNA in phytochemicals-based therapy of cancer, and updates on phytochemicals-based translation research on therapy for metastatic cancer.